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The epidermal growth factor (EGF)2 receptor is a transmembrane receptor tyrosine kinase that is the founding member of
the ErbB receptor family (1, 2). It contains an extracellular
ligand-binding domain, a single-pass transmembrane domain,
an intracellular tyrosine kinase domain, and an intrinsically disordered C-terminal tail (3). The signal of ligand binding is
transduced through the structure of the receptor and results in
the activation of the intracellular tyrosine kinase domain. Phosphorylation of tyrosines on the C-terminal tail of the EGF
receptor (4 –6) generates binding sites for the Src homology 2
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(SH2) and PTB domain-containing proteins that mediate the
downstream effects of growth factor binding (7).
In the absence of ligand, the EGF receptor is thought to exist
as a monomer in which the extracellular domain adopts a
closed, tethered conformation (8). This closed conformation is
mediated by interactions between the dimerization arm in subdomain II and the tethering arm in subdomain IV of the extracellular domain. Upon ligand binding, this tether is released
and the receptor opens into an extended conformation. This
exposes the dimerization arm in subdomain II, allowing two
EGF receptor monomers to form a back-to-back dimer via their
now-exposed dimerization arms (9, 10). The EGF receptor also
appears to form ligand-independent dimers but consensus is
lacking regarding the structure of these dimers (11, 12).
EGF-induced dimerization of the extracellular domain
induces the formation of an asymmetric dimer of the intracellular kinase domains (13). In this dimer, the C-terminal lobe of
the activator kinase interacts with the N-terminal lobe of the
receiver kinase resulting in the activation of the receiver kinase.
Mutations that ablate this interface also abolish receptor tyrosine kinase activity. The kinase domains can also form a symmetric “head-to-head” dimer but this species is catalytically
inactive (14).
ATP-competitive, small-molecule inhibitors of the EGF
receptor kinase have been developed and many of them are in
widespread clinical use (15). Two types of inhibitors have been
identified (16). Type I inhibitors, such as erlotinib, bind to the
active conformation of the kinase domain in which the important ␣-C helix is swung in to the active site (17). Type II inhibitors, such as lapatinib, bind to the inactive conformation of the
kinase domain in which the ␣-C helix is swung out (18). Despite
the fact that both inhibitors block EGF receptor tyrosine kinase
activity, they show differential efficacy in different tumor types
(19 –21). This suggests that they possess other properties,
besides kinase inhibition, that distinguish their effects on
tumorigenic forms of the EGF receptor.
In this study, we show that in addition to inhibiting EGF
receptor kinase activity, these inhibitors modulate the function
of the extracellular ligand-binding domain with erlotinib
increasing and lapatinib decreasing receptor-binding affinity.
Our data suggest that the conformations of the EGF receptor
extracellular domain and intracellular kinase domain are coupled and that these high affinity and low affinity conformations
exist in an equilibrium that can be shifted by small-molecule
tyrosine kinase inhibitors. Our studies also reveal unexpected
J. Biol. Chem. (2018) 293(35) 13401–13414
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The epidermal growth factor (EGF) receptor is a classical
receptor tyrosine kinase with an extracellular ligand-binding
domain and an intracellular kinase domain. Mutations in the
EGF receptor have been shown to drive uncontrolled cell
growth and are associated with a number of different tumors.
Two different types of ATP-competitive EGF receptor tyrosine
kinase inhibitors have been identified that bind to either the
active (type I) or inactive (type II) conformation of the kinase
domain. Despite the fact that both types of inhibitors block tyrosine kinase activity, they exhibit differential efficacies in different tumor types. Here, we show that in addition to inhibiting
kinase activity, these inhibitors allosterically modulate ligand
binding. Our data suggest that the conformations of the EGF
receptor extracellular domain and intracellular kinase domain
are coupled and that these conformations exist in equilibrium.
Allosteric regulators, such as the small-molecule tyrosine kinase
inhibitors, as well as mutations in the EGF receptor itself, shift
the conformational equilibrium among the active and inactive
species, leading to changes in EGF receptor-binding affinity.
Our studies also reveal unexpected positive cooperativity
between EGF receptor subunits in dimers formed in the presence of type II inhibitors. These findings indicate that there is
strong functional coupling between the intracellular and extracellular domains of this receptor. Such coupling may impact the
therapeutic synergy between small-molecule tyrosine kinase
inhibitors and monoclonal antibodies in vivo.
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positive cooperativity between EGF receptor subunits in
dimers formed in the presence of type II inhibitors and some
EGF receptor mutants. These findings indicate that there is
strong structural and functional coupling between the intracellular and extracellular domains of this receptor. Knowledge of
this coupling could be exploited to enhance the efficacy of combinations of extracellular-directed and kinase-directed EGF
receptor therapeutics.

Results
Erlotinib and lapatinib alter the ligand-binding properties of
the EGF receptor
Treatment of CHO cells expressing the EGF receptor with
the tyrosine kinase inhibitor, erlotinib, was found to significantly increase the affinity of the receptor for EGF (Fig. 1A)
from an EC50 of ⬃3 nM in untreated cells to an EC50 of ⬃0.3 nM
after treatment with erlotinib. To determine whether this effect
was due to the inhibition of receptor kinase activity, we also
assessed the effect on EGF binding of lapatinib, another smallmolecule inhibitor of the EGF receptor kinase. Treatment of
cells with lapatinib led to a modest decrease in the affinity of
EGF for its receptor (Fig. 1B).
Erlotinib is a type I inhibitor that binds to the active conformation of the EGF receptor kinase (17), whereas lapatinib is a
type II inhibitor that binds to the inactive conformation of the
kinase (18). To determine whether the different effects of erlotinib and lapatinib on EGF-binding affinity were due to the
different conformations of the kinase domain to which they
bound, we assessed the effects of gefitinib and neratinib on
125
I-EGF binding.
The data in Fig. 1C demonstrate that, like erlotinib, the type
I inhibitor, gefitinib (22), also increased the affinity of the receptor for EGF. An increase in EGF binding due to treatment with
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gefitinib has been observed previously (23). Neratinib, a type II
inhibitor (24), recapitulated the effects of lapatinib, modestly
reducing the affinity of the receptor for EGF (Fig. 1D). These
data are consistent with the conclusion that the effects of these
four inhibitors on EGF binding are related to their ability to
shift the EGF receptor kinase domain into either the active
(erlotinib and gefitinib) or inactive (lapatinib and neratinib)
conformations. This implies that the conformation of the intracellular kinase domain modulates the function of the extracellular ligand-binding domain.
To determine whether either of these effects on receptor
binding were related to inhibition of kinase activity, we assessed
the effects of erlotinib and lapatinib on two kinase-dead versions of the EGF receptor, the D813N-EGF receptor (Fig. 2, A
and B) and the K721A-EGF receptor (Fig. 2, C and D). As can be
seen from Fig. 2, A and C, an erlotinib-induced increase in EGF
affinity was still seen in both kinase-dead receptors. Thus, the
observed increase in affinity upon treatment with erlotinib
appears to be independent of its ability to inhibit the kinase
activity of the EGF receptor. By contrast, the effect of lapatinib
was largely abolished in the kinase-dead receptors (Fig. 2, B
and D).
Although these data suggest that the effects of lapatinib may
be due to its ability to inhibit the kinase activity of the EGF
receptor, the results with other mutants suggest that the situation is more complicated than that. The data in Fig. 2, E and F,
show the response of the c⬘973-EGF receptor to treatment with
erlotinib or lapatinib. The c⬘973-EGF receptor is truncated at
residue 973, just before the first phosphorylatable tyrosine in
the C-terminal tail. This truncation removes most of the C-terminal tail, precluding any autophosphorylation of the receptor.
However, the kinase remains active and is, in fact, transforming
(25). As was observed with the two kinase-dead receptors, the
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Figure 1. Effect of EGF receptor tyrosine kinase inhibitors on EGF affinity. CHO cells expressing the WT EGF receptor were treated for 30 min at 37 °C
without or with the indicated inhibitor prior to binding of 125I-EGF overnight at 4 °C. The indicated inhibitor was also included in the binding incubation
medium. Points represent the mean ⫾ S.D. of triplicate determinations in a single experiment, which was repeated a minimum of three times.
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Figure 2. Effect of erlotinib and lapatinib on EGF affinity in EGF receptor mutants. CHO cells expressing the D813N-EGF receptor (A and B), the K721A-EGF
receptor (C and D), the c⬘973-EGF receptor (E and F), or the Y9F-EGF receptor (G and H) were treated for 30 min at 37 °C without (black lines) or with erlotinib
(green lines) or lapatinib (red lines) prior to binding of 125I-EGF overnight at 4 °C. The indicated inhibitor was also included in the binding incubation medium.
Points represent the mean ⫾ S.D. of triplicate determinations in a single experiment, which was repeated a minimum of three times.
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counts bound (⬃75%) at low concentrations of unlabeled, competing ligand in the lapatinib-treated condition is a reflection of
the lapatinib-induced decrease in affinity observed in the saturation-binding curves. As with erlotinib, the difference between
the control and lapatinib-treated curves was largest at low
doses of competitor but minimal at higher concentrations of
unlabeled competitor. Thus, like erlotinib, lapatinib appears to
exert its effect by reducing the fraction of high affinity sites so
the overall population average affinity is decreased.
This bell-shaped binding behavior was relatively subtle in the
WT receptor but was very obvious in the kinase-dead D813NEGF receptor (Fig. 3D). This mutant exhibited bell-shaped
competition-binding curves both in the absence and presence
of lapatinib. For this kinase-dead mutant, the addition of lapatinib did not substantially reduce 125I-EGF binding at low concentrations of unlabeled ligand, consistent with the absence of a
lapatinib-induced decrease in binding affinity (Fig. 2B). Interestingly, the kinase-dead K721A-EGF receptor exhibited a bellshaped curve only in the presence of lapatinib (Fig. 3F) and
showed only a modest decrease (⬃30%) in the amount of 125IEGF bound initially as compared with the WT receptor. Thus,
the two kinase-dead versions of the EGF receptor exhibited
distinct properties. This may be due to differences in the structural effects of the two mutations. D813N mutates a residue
important for catalysis (31), whereas K721A removes a residue
that stabilizes the active configuration of the kinase domain
(13).
Both the c⬘973-EGF receptor and Y9F-EGF receptor exhibited behavior very similar to that of the WT EGF receptor,
showing a bell-shaped competition-binding curve only in the
presence of lapatinib and an ⬃70% decrease in 125I-EGF binding upon addition of lapatinib to the cells (Fig. 3H). Thus, the
ability of lapatinib to induce positive cooperativity in EGF binding is independent of the status of the C-terminal tail.
Effects of kinase inhibitors require receptor dimerization
Erlotinib has been shown to induce kinase-mediated dimerization of the EGF receptor (32–34). The presence of positive cooperativity in EGF binding in lapatinib-treated cells
implies that lapatinib allows the formation of some type of EGF
receptor dimer. Therefore, we next examined the influence of
mutations in the subunit–subunit interfaces in the EGF receptor on the ability of these inhibitors to modulate ligand binding.
The Y246D-EGF receptor has a mutation in the dimerization
arm of extracellular subdomain II that largely abolishes the ability of the receptor to form back-to-back dimers upon binding
ligand (9, 10). As shown in Fig. 4A, the Y246D mutation markedly diminished, but did not eliminate, the ability of erlotinib to
enhance the affinity of EGF. The effect of lapatinib on EGF
binding also appeared to be blunted by the Y246D mutation
(Fig. 4B). These data suggest that dimerization of the extracellular domain contributes to the effects of these inhibitors on
EGF binding.
The D563A,H566A,K585A mutation (referred to hereinafter
as DHK-EGFR) is in the tethering arm in subdomain IV of the
EGF receptor. This triple mutation removes the major interactions in the subdomain II–subdomain IV tether that holds the
EGF receptor in the closed conformation (8). As can be seen in
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c⬘973-EGF receptor showed a large increase in affinity following treatment with erlotinib but no change in affinity upon
treatment with lapatinib. Thus, the lack of effect of lapatinib
on EGF affinity in the two kinase-dead receptors cannot be
attributed to their lack of kinase activity because lapatinib
also failed to reduce ligand affinity in the kinase-active
c⬘973-EGF receptor.
The failure of lapatinib to induce a decrease in the affinity of
the c⬘973-EGF receptor may be related to the absence of the
C-terminal tail in this mutant. The Y9F-EGF receptor is a
mutant in which all nine tyrosines in the C-terminal tail have
been replaced with phenylalanines. As a result, the tail cannot
undergo autophosphorylation (26). Nevertheless, this receptor
showed both an increase in affinity in the presence of erlotinib
(Fig. 2G) and a decrease in affinity in the presence of lapatinib
(Fig. 2H). Thus, the presence of the C-terminal tail, but not
its phosphorylation, is permissive for the lapatinib-induced
decrease in EGF affinity.
Although not obvious from the saturation-binding curves
shown in Figs. 1 and 2, lapatinib was also found to induce an
allosteric change in ligand binding by the EGF receptor. This is
apparent when the data are plotted as 125I-EGF competitionbinding curves, in which a fixed concentration of 125I-EGF is
competed off the receptor by the addition of increasing concentrations of unlabeled EGF. In contrast to the saturation-binding
curves, this format highlights differences seen at low concentrations of competing ligand. This is because the number of
counts of 125I-EGF bound is greatest when little or no cold
competitor has been added.
Typically, there is a monotonic decline in the binding of 125IEGF as the concentration of unlabeled EGF is increased. This is
observed in the WT EGF receptor both in the absence or presence of erlotinib (Fig. 3A). The increase in 125I-EGF bound at
low doses of unlabeled EGF in the presence of erlotinib is due to
the erlotinib-induced increase in the overall affinity of the
receptor for EGF as seen in the saturation plots (Fig. 1A). This
same pattern of a monotonic decrease in 125I-EGF binding as
the dose of unlabeled competitor increases was observed for the
D813N-EGF receptor (Fig. 3C), the K721A-EGF receptor (Fig.
3E), the c⬘973-EGF receptor (Fig. 3G), and the Y9F-EGF receptor (Fig. 3I) when assayed in the presence of erlotinib.
The EGF receptor shows heterogeneity in its binding affinity
for EGF, exhibiting both high affinity (⬃200 pM) and low affinity (⬃3 nM) binding sites (27–30). These affinity states are interconvertible and are due to the formation of predimers as well as
to the presence of negative cooperativity in the system (28). At
low concentrations of EGF, binding takes place almost exclusively at the high affinity site. Thus, the increase in counts
bound by erlotinib-treated cells at low doses of EGF suggests
that erlotinib increases the fraction of receptors in the high
affinity state rather than increasing the affinity of the low affinity form of the receptor.
Unexpectedly, treatment of cells expressing the WT EGF
receptor with lapatinib resulted in a bell-shaped competitionbinding curve (Fig. 3B), an indication of the presence of positive
cooperativity. Positive cooperativity is seen when the binding of
a ligand to the first site on a dimer enhances the affinity of the
second site on the dimer for that ligand. The large decrease in
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Figure 3. 125I-EGF competition-binding curves of WT and mutant EGF receptors treated without or with erlotinib or lapatinib. CHO cells expressing the
indicated EGF receptors were treated without (black lines) or with erlotinib (green lines) or lapatinib (red lines) prior to and during incubation with labeled EGF.
Increasing concentrations of unlabeled EGF were added to different wells. The data are normalized to control binding. Control binding represents the number
of counts of 125I-EGF bound by the untreated cells in the absence of any additional unlabeled EGF. Points represent the mean ⫾ S.D. of triplicate determinations
in a single experiment, which was repeated a minimum of three times.
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Figure 4. Effect of erlotinib and lapatinib on EGF receptors with mutations in subunit–subunit interfaces. CHO cells expressing the Y246D-EGF receptor
(A and B), the D563A,H566A,K585A-EGF receptor (C and D), the T548R,N554R-EGF receptor (E and F), or the V924R-EGF receptor (G and H) were treated for 30
min at 37 °C without (black lines) or with erlotinib (green lines) or lapatinib (red lines) prior to binding of 125I-EGF overnight at 4 °C. The indicated inhibitor was
also included in the binding incubation medium. Points represent the mean ⫾ S.D. of triplicate determinations in a single experiment, which was repeated a
minimum of two times.
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treatment of these cells with erlotinib or lapatinib, respectively.
Interestingly, treatment with lapatinib did not result in a bellshaped competition-binding curve, suggesting that the positive
cooperativity observed in other receptors may be related to
release of the intramolecular tether in the extracellular domain
of the receptor.
Mutation of the oligomerization interface in the TN/RR-EGF
receptor did not affect the response of this receptor to either
erlotinib (Fig. 5E) or lapatinib (Fig. 5F). Erlotinib induced a
large increase in the amount of 125I-EGF bound at low doses of
competitor. Lapatinib treatment resulted in a decrease in binding and produced a bell-shaped competition-binding curve,
demonstrating the presence of positive cooperativity in this
receptor. Thus, the observed cooperativity does not appear to
be due to formation of higher order EGF receptor oligomers.
The competition-binding curves of the V924R-EGF receptor
were highly unusual. Like the D813N-EGF receptor, the competition-binding curve for the V924R-EGFR was bell-shaped
even in the absence of an inhibitor (Fig. 5G). But surprisingly,
whereas there was a small increase in affinity upon addition of
erlotinib, as evidenced by the increase in EGF binding, the competition-binding curve remained bell-shaped after treatment
with this type I inhibitor. The V924R-EGF receptor was the
only mutant that could not be converted to a monotonically
decreasing competition-binding curve by the addition of erlotinib. Lapatinib did not significantly affect the competitionbinding curve of the V924R-EGF receptor (Fig. 5H). These data
suggest that the ability to form the asymmetric dimer is central
to the effects of both erlotinib and lapatinib on EGF binding.
Effect of kinase inhibitors on mutationally activated EGF
receptors
The foregoing data suggest that the effect of erlotinib on EGF
binding is due to its ability to promote the formation of the
active conformation of the kinase and the activating asymmetric dimer. L834R is a mutation in the kinase domain of the EGF
receptor that is commonly seen in lung cancer (39). Shan et al.
(40) reported that the L834R mutation activated the EGF receptor kinase by suppressing disorder in the ␣-C helix, thereby
promoting the formation of the active asymmetric kinase
dimer. If the ability of erlotinib to increase EGF-binding affinity
(41) is due to its ability to order the ␣-C helix and promote the
formation of the asymmetric dimer, we postulated that the
effect of erlotinib would be blunted in the L834R-EGF receptor,
which already favors the formation of asymmetric dimers
under basal conditions.
Fig. 6A shows the effect of erlotinib on the binding of EGF to
cells expressing the L834R-EGF receptor. In this cell line, the
affinity for EGF in the untreated cells was noticeably higher
(⬃0.9 nM) than that observed in cells expressing the WT EGF
receptor (⬃3 nM). Consistent with our hypothesis, treatment
with erlotinib resulted in only a 3-fold increase in EGF affinity
for the L834R-EGF receptor, substantially less than the ⬃10fold seen in WT receptors. This reduction in the erlotinib effect
is seen in the competition-binding curves (Fig. 6C), which are
monotonic in the absence or presence of erlotinib. But erlotinib
induced a relatively small increase in binding (⬃50%) at low
J. Biol. Chem. (2018) 293(35) 13401–13414
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Fig. 4C, treatment with erlotinib increased the affinity of the
DHK-EGF receptor for EGF ⬃9-fold, similar to what is seen
in the WT EGF receptor. Treatment of cells expressing the
DHK-EGF receptor with lapatinib resulted in a typical ⬃2-fold
decrease in EGF affinity (Fig. 4D). Thus, based on saturationbinding curves this triple mutation had little effect on ligand
binding other than a slight increase in affinity relative to the
WT EGF receptor. This effect has been noted previously (8).
The EGF receptor has frequently been reported to form
higher order oligomers (35–38). A recent study from the Kuriyan laboratory (38) implicated a portion of extracellular subdomain IV in the formation of EGF receptor multimers. In particular, a mutation in which Thr-548 and Asn-554 were each
substituted with Arg (TN/RR-EGF receptor) significantly
reduced the formation of multimers. To determine whether the
effects of erlotinib or lapatinib were dependent on the ability of
the EGF receptor to multimerize, we examined the effect
of these inhibitors on the binding of EGF in cells expressing the
TN/RR-EGF receptor. The data in Fig. 4, E and F, demonstrate
that the behavior of this mutant was very similar to that of the
WT EGF receptor, suggesting that the effect of these inhibitors
on receptor affinity is not due to an effect on receptor
multimerization.
We next determined whether dimerization of the kinase
domain was required for the effects of erlotinib and lapatinib on
ligand affinity. The V924R mutation of the EGF receptor alters
the activator interface of the kinase domain, impairing its ability to form an activated asymmetric dimer (13). The ability of
erlotinib to elicit an increase in EGF affinity was almost completely eliminated in the V924R-EGF receptor (Fig. 4G). Likewise, the ability of lapatinib to induce a decrease in receptor
affinity was suppressed by this mutation (Fig. 4H). Thus, formation of the asymmetric kinase dimer appears to play a major role
in the modulation of ligand-binding affinity by EGF receptor
kinase inhibitors.
Fig. 5 shows the corresponding competition-binding curves
for these mutants. As expected, the competition-binding
curves for the Y246D-EGF receptor were monotonic in the
absence of inhibitor and in the presence of erlotinib (Fig. 5A).
The fact that erlotinib induced a significant increase in the
binding of 125I-EGF at the lowest concentrations of unlabeled
EGF competitor is consistent with the modest overall increase
in affinity for EGF seen in the saturation-binding curves (Fig.
4A). This suggests that the effect of erlotinib does not depend
entirely on the formation of a back-to-back dimer. Lapatinib
treatment resulted in only a small decrease in 125I-EGF binding
at low doses of competitor, again consistent with the small
decrease in overall affinity seen in the saturation-binding
curves (Fig. 4B). Notably, lapatinib did not induce a bell-shaped
competition-binding curve, implicating the formation of backto-back dimers in the positive cooperativity observed in the
presence of this type II inhibitor.
The data in Fig. 5, C and D, demonstrate that treatment
of cells expressing the DHK-EGF receptor with erlotinib
increased the amount of 125I-EGF bound at low doses of competitor, whereas treatment with lapatinib reduced the amount
of 125I-EGF bound at low doses of competitor. This necessarily
follows from the increase and decrease in affinity seen after

Regulation of EGF binding by tyrosine kinase inhibitors

Downloaded from http://www.jbc.org/ at Washington University on November 19, 2019

Figure 5. 125I-EGF competition-binding curves of EGF receptors with mutations in subunit–subunit interfaces treated without or with erlotinib or
lapatinib. CHO cells expressing the indicated EGF receptors were treated without (black lines) or with erlotinib (green lines) or lapatinib (red lines) prior to and
during incubation with labeled EGF. Increasing concentrations of unlabeled EGF were added to different wells. The data are normalized to control binding.
Control binding represents the number of counts of 125I-EGF bound by the untreated cells in the absence of any additional unlabeled EGF. Points represent the
mean ⫾ S.D. of triplicate determinations in a single experiment, which was repeated a minimum of two times.

doses of cold competitor compared with what is normally seen
in the WT EGF receptor (⬃400%).
Treatment of cells expressing the L834R-EGFR with lapatinib produced an ⬃2-fold decrease in the EC50 for EGF (Fig.
6B), similar to what was seen for WT EGF receptors treated
with lapatinib. This should be considered the minimum effect
of lapatinib in this line as the L834R has a reduced affinity for
lapatinib as compared with the WT EGF receptor (41). Inter-

13408 J. Biol. Chem. (2018) 293(35) 13401–13414

estingly, lapatinib failed to induce a bell-shaped competitionbinding curve, suggesting that the mutation overcomes the
effect of lapatinib on ligand binding.
Not all transforming mutations blunted the effect of erlotinib. The V665M-EGFR carries a point mutation in the juxtamembrane latch of the receptor that enhances the stability
of the asymmetric kinase dimer, but does not affect the conformation of the ␣-C helix (42). Like the L834R-EGFR, the
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Figure 6. Saturation-binding curves and 125I-EGF competition-binding curves of mutationally activated EGF receptors. CHO cells expressing the
L834R-EGF receptor (A–D) or the V665M-EGF receptor (E–H) were treated without (black lines) or with erlotinib (green lines) or lapatinib (red lines) prior to and
during incubation with increasing concentrations of 125I-EGF. Data are shown as saturation-binding curves (A, B, E, and F) or competition-binding curves (C, D,
G, and H). Points represent the mean ⫾ S.D. of triplicate determinations in a single experiment, which was repeated a minimum of three times.
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V665M-EGFR exhibited a slightly increased affinity for EGF
in untreated cells (Fig. 6E). But in contrast to the L834R-EGFR,
addition of erlotinib to cells expressing the V665M-EGFR
resulted in a further ⬃10-fold increase in affinity that is typical
for the WT EGF receptor (Fig. 6G).
Lapatinib induced an ⬃2-fold decrease in affinity in the
V665M-EGFR (Fig. 6F) as reflected in the ⬃75% decrease of
125
I-EGF bound initially in the competition-binding curve (Fig.
6H). In addition, as in the WT EGF receptor, the V665M-EGFR
exhibited a bell-shaped competition-binding curve in the presence of lapatinib. Thus, although both the L834R and V665M
mutations activate the EGF receptor kinase, only the L834R
mutation that affects the conformation of the ␣-C helix alters
the effect of erlotinib on ligand binding.

Discussion
The binding of EGF promotes the dimerization and activation of the EGF receptor kinase domain. The experiments
reported here demonstrate that, reciprocally, the binding of
small-molecule inhibitors to the kinase domain allosterically
regulate the function of the ligand-binding domain of the
receptor. Previous studies that assessed the effect of small-molecule inhibitors on the extracellular domain of the EGF receptor looked only for structural changes and found none (43, 44).
Our analysis of the effects of these inhibitors on ligand binding
clearly demonstrates that there is significant functional linkage
between the extracellular domain and the intracellular domain
of the EGF receptor.
The binding of EGF to its receptor is known to promote the
formation of a back-to-back dimer of the extracellular domains
of the receptor. Our finding that the binding affinity for EGF is

13410 J. Biol. Chem. (2018) 293(35) 13401–13414

different in the presence of erlotinib or lapatinib suggests that
the dimers formed in the presence of these two inhibitors are
different. Indeed, Mi et al. (44) showed that in the presence of
erlotinib, EGF induced the formation of a back-to-back dimer
of the extracellular domain coupled to a rod-like, asymmetric
kinase dimer of the intracellular domain. By contrast, in the
presence of lapatinib, the extracellular domain adopted the
back-to-back dimer configuration but the kinase domain
formed distinct (inactive) globular dimers or unassociated
monomers. Our data indicate that even though the extracellular domains appear to form structurally similar dimers when
erlotinib or lapatinib are bound to the kinase domain, the distinct conformations of the kinase domains induced by these
inhibitors differentially affect the ligand-binding properties of
the extracellular domain dimers.
The difference in the conformation of the kinase domains in
the erlotinib- versus lapatinib-bound dimers is likely responsible for the difference in allosteric interactions between the two
subunits in the dimer. Pretreatment with lapatinib, but not with
erlotinib, resulted in bell-shaped competition-binding curves,
indicative of positive cooperativity. Positive cooperativity
implies the existence of a dimer that binds the first ligand with
low affinity but the second ligand with higher affinity. This is
exactly the opposite of what is typically seen for the untreated
EGF receptor, which exhibits negative cooperativity within
receptor dimers (28, 45). This again underscores the functional
coupling between the intracellular and extracellular domains of
the EGF receptor.
Fig. 7 shows a model of how we envision these kinase inhibitors modulating EGF binding. Erlotinib and gefitinib are type I
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Figure 7. Schematic diagram of the proposed effects of erlotinib and lapatinib on the conformation and dimerization of the EGF receptor. The
ordered, active conformation (green) and ordered, inactive conformation (red) of the kinase domain are in equilibrium with an intermediate conformation of
the kinase domain in which the ␣-C helix is disordered (yellow). Erlotinib stabilizes the active conformation of the kinase domain, which can form asymmetric
dimers and which is linked to the open conformation of the extracellular domain. Lapatinib stabilizes the inactive conformation of the kinase domain, which
forms symmetric dimers, which are linked to the tethered conformation of the extracellular domain.
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meric receptor (50). Finally, the L834R mutation has been
shown to increase the tendency of the kinase domain to adopt
its active conformation (40). Furthermore, Valley et al. (51)
have reported that the L834R-EGF receptor is dimerized and its
extracellular domain is in a more extended form than that of the
WT receptor. In our experiments, treatment of the L834R-EGF
receptor with erlotinib induced a smaller than usual increase in
ligand affinity, suggesting that the L834R mutation and erlotinib treatment have similar and overlapping effects on receptor conformation and affinity. Together, these data suggest that
type I inhibitors and mutations that alter the ␣-C helix and
promote asymmetric dimer formation, induce the release of
tethering interactions in the extracellular domain, allowing the
extracellular domain of the receptor to adopt a more extended
conformation.
Few data are available regarding the conformation of the
ligand-free extracellular domain of the EGF receptor when the
kinase domain is occupied by lapatinib. The inhibitor does not
induce dimerization of the receptor (33, 46) so the conformation must be similar to that of the unoccupied EGF receptor
monomer. In the absence of EGF, the soluble extracellular
domain adopts the closed tethered conformation (8, 52). Bessman et al. (12) showed that Fc-mediated dimerization of the
EGF receptor does not enforce the traditional back-to-back
extended conformation on the soluble extracellular domain.
Rather, it results in the formation of a mixture of conformations
that contain the tethered form of the extracellular domain of
the receptor. The closed form of the receptor would exhibit a
lower affinity for EGF as some of the binding energy would be
expended to open the receptor into a conformation that can
bind ligand with both subdomains I and III. It therefore seems
likely that the lapatinib-bound form of the receptor is linked to
a closed form of the extracellular domain.
The results with the c⬘973-EGF receptor suggest that the
C-terminal tail of the receptor is involved in setting the position
of the conformational equilibrium of the receptor. In the
absence of the tail, the population average affinity was low and
not reduced by lapatinib, suggesting that the receptor had
shifted toward its inactive conformation. By contrast, the nonphosphorylatable Y9F-EGF receptor behaved similarly to the
WT receptor, indicating that the physical presence of the tail,
not its phosphorylation, regulates the position of the conformational equilibrium of the receptor. This was unexpected
because the C-terminal tail has been reported to exert an inhibitory influence on the EGF receptor kinase (33, 53). However, it
is possible that in the absence of the tail, the binding of an
inhibitory protein such as Mig6 (54) is facilitated and this shifts
the equilibrium toward the inactive conformation.
The presence of positive cooperativity in lapatinib-bound
dimers but not in erlotinib-bound dimers clearly suggests that
the conformation of the kinase domain, and in particular the
position of the ␣-C helix, significantly alters the subunit–
subunit interactions in EGF-induced dimers. Binding of EGF to
a lapatinib-occupied EGF receptor monomer occurs with low
affinity and must induce formation of a singly occupied dimer
in which the kinase domain forms an inactive symmetric dimer
(44). The binding of EGF would stabilize the ligand-occupied
subunit in its open, extended conformation. This may lead to
J. Biol. Chem. (2018) 293(35) 13401–13414
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inhibitors that preferentially bind to the active conformation of
the kinase domain (17) and induce the formation of an asymmetric kinase dimer (13, 46) (shown in green in Fig. 7). By contrast, lapatinib and neratinib are type II inhibitors that bind to
the inactive conformation of the kinase domain (18) (shown as
red squares in Fig. 7).
We interpret our data in the context of the report of Shan et
al. (40) that EGF receptor kinase monomers exist in an equilibrium of three different conformations: (i) an active conformation of the kinase in which the ␣-C helix is ordered and swung
in, (ii) a Src/CDK2-like inactive conformation in which the ␣-C
helix is ordered but swung out and, (iii) an intermediate conformation in which the ␣-C helix is in a disordered conformation. We propose that, in the absence of ligand, the two ordered
conformations of the intracellular kinase domain are linked to
distinct conformations of the extracellular ligand-binding
domain that exhibit different affinities for EGF. Specifically, the
active conformation of the kinase is linked to an untethered,
largely extended conformation of the extracellular domain that
has a high affinity for EGF and the inactive conformation of the
kinase is linked to a closed, likely tethered, conformation of the
extracellular domain that has a low affinity for EGF. The disordered conformation of the kinase domain is associated with an
intermediate conformation of the extracellular domain that
may be untethered and can adopt either the open or closed
conformation.
The population of EGF receptors in any given cells is an equilibrium mixture of all conformations of the receptor and this
population exhibits binding characteristics that reflect the distribution of the receptor between high and low affinity forms.
Type I inhibitors shift the equilibrium toward the active conformation of the kinase linked to the high affinity form of the
extracellular domain. This leads to a population average
increase in affinity. Type II inhibitors shift the equilibrium
toward the inactive conformation of the kinase that is linked to
the low affinity form of the kinase domain. This decreases the
population average affinity. Mutations in the EGF receptor,
such as V924R or L834R, can also shift the position of the basal
equilibrium among these species, leading to changes in the
apparent effect of erlotinib or lapatinib on receptor affinity.
A variety of data support the assignment of the extended
form of the extracellular domain to the active conformation of
the kinase domain. First, the EGF receptor is thought to be
held in the closed conformation through the subdomain
II–subdomain IV tether (8). It has been estimated that this tethering energy is enough to generate a 5–30-fold increase in affinity and such affinity increases have been documented when the
tether is removed or mutated (8, 47, 48). The 10-fold increase in
affinity that we see in the presence of erlotinib is in this range,
consistent with the hypothesis that erlotinib destabilizes the
subdomain II–subdomain IV tethering interaction, allowing
the receptor to adopt a more open, extended conformation. In
addition, tyrphostin, another type I tyrosine kinase inhibitor,
has been shown to induce the formation of an untethered, transitional form of the EGF receptor that is recognized by mAb806
(49). mAb806 binds to an epitope encompassing residues 287–
302 that is hidden in both the tethered and dimerized forms of
the extracellular domain but available in the extended mono-
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Experimental procedures
Materials
The CHO-K1 Tet-On cell line, the pBI-Tet vector, and doxycycline were from Clontech (Mountain View, CA). FetalPlex
was from Gemini Bioproducts. EGF was from Biomedical
Technologies. Na125I was from Perkin Elmer. Erlotinib,
gefitinib, and neratinib were from Selleck Chemicals. Lapatinib
was from VWR. Cetuximab and pertuzumab were obtained
from the Barnes-Jewish Hospital pharmacy.
Cells and tissue culture
All EGF receptors were expressed in CHO-K1 cells from pBITet, using the Tet-on induction system from Clontech. The
construction of these lines has been reported previously (28,
56 –58). Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% FetalPlex, 1000 g/ml of
penicillin/streptomycin, 100 g/ml of G418, and 100 g/ml of
hygromycin. Cells were plated onto lysine-coated 6-well dishes
24 h prior to use. The concentration of doxycycline used to
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induce receptor expression varied among cell lines but was chosen to yield a level of expression of about 200,000 –300,000
receptors/cell.
125

I-EGF synthesis and binding

125

I-EGF was synthesized using the oxidative ICl procedure
of Doran and Spar (59). For radioligand binding studies, cells in
6-well dishes were incubated for 30 min at 37 °C in DMEM, 50
mM HEPES, pH 7.4, containing 5 mg/ml of BSA in the absence
or presence of 5 M erlotinib, 10 M lapatinib, 50 M gefitinib,
or 5 M neratinib. Cells were then placed on ice, washed twice
in ice-cold PBS, and incubated overnight at 4 °C in DMEM, 50
mM HEPES, pH 7.4, 5 mg/ml of BSA, without or with the indicated concentration of inhibitor and containing 20 – 40 pM 125IEGF plus increasing concentrations of unlabeled EGF. Pertuzumab (5 g/ml) was included in all binding assays to preclude
heterodimerization of the EGF receptor with the few ErbB2
receptors present in these cells. We have shown that there are
no ErbB3 or ErbB4 receptors in these CHO cells (26).
At the end of the incubation, cells were washed three times in
ice-cold PBS and the monolayers dissolved in 1 N NaOH. The
solution was transferred to tubes, which were counted for 125I
in a Beckman Gamma Counter. Assays were done in triplicate.
For competition-binding curves, the data were fit to the
log(inhibitor) versus response (variable slope) equation in
GraphPad Prism 7,
Y ⫽ bottom ⫹ 共top-bottom兲/共1 ⫹ 10共共logIC50⫺X兲⫻h兲兲
(Eq. 1)
125

where Y is the cpm of I-EGF bound, X is the log of the concentration of cold, competing EGF, top and bottom are the
fitted maximum and minimum counts, IC50 is the value of X
that achieves half-maximal inhibition, and h is the Hill slope.
For competition-binding curves showing positive cooperativity, the data were fit to the equation for a bell-shaped doseresponse curve,
Y ⫽ 关 B ⬁ ⫺ B max/1 ⫹ 10共共logEC50_1⫺X兲⫻h1兲兴 ⫹ 关B0 ⫺ Bmax/1
⫹ 10共共X ⫺ logEC50_2)⫻h2兲兴 (Eq. 2)
where X is the log of the concentration of unlabeled EGF, B0 is
the cpm bound in the absence of added competitor, Bmax is the
cpm bound at the peak of binding, B∞ is cpm bound at infinite
[X], EC50_1 is the EC50 for the first (upward) part of the curve, h1
is the corresponding Hill slope, EC50_2 is the EC50 for the second (downward) part of the curve, and h2 is the corresponding
Hill slope.
For saturation-binding curves, nonspecific binding was
determined by fitting the raw data to a competition-binding
model and using the fitted bottom value as the nonspecific
binding. The data corrected for nonspecific binding were converted to direct binding curves using the known specific activity
of the 125I-EGF and were fitted to the equation,
Y ⫽ B max ⫻ Xh/共EC50h ⫹ Xh兲

(Eq. 3)

where Y is ligand binding at concentration X of ligand. Bmax is
the amount of ligand bound at saturating concentrations of

Downloaded from http://www.jbc.org/ at Washington University on November 19, 2019

conformational changes that weaken the tether in its partner
receptor or may simply trap the other subunit when it momentarily flickers into an open conformation. This open singly
occupied dimer must have a higher affinity for EGF than does
the closed monomeric form. This would give rise to the
observed positive cooperativity.
The V924R-EGF receptor exhibited positive cooperativity
even in the absence of lapatinib. This is likely because this
receptor can never form a proper asymmetric kinase dimer and
so is found almost exclusively in the inactive conformation.
Indeed, Mi et al. (44) showed that the EGF-bound V924R-EGF
receptor was coupled to symmetric kinase dimers, just like the
lapatinib-bound WT receptor. The D813N mutant also showed
striking positive cooperativity in the absence of lapatinib. This
suggests that the D813N mutation stabilizes the kinase domain
in the Src/CDK2-like inactive state. In the structure of the symmetric kinase dimer (14), Asp-813 is close to Asp-831. If Asp813 is converted to Asn, an Asn-813–Asp-831 hydrogen bond
could form that would stabilize the inactive conformation of
the kinase domain, potentially favoring symmetric dimer formation. Unlike the V924R-EGF receptor, the D813N-EGF
receptor can form a stable asymmetric dimer and is shifted into
this conformation by erlotinib.
The concept that a particular conformation of the intracellular kinase domain is linked to a specific conformation of the
extracellular domain could aid in the rational design of combination therapies directed against the EGF receptor. For example, the inhibitory activity of lapatinib is likely to be enhanced
by antibodies that stabilize the tethered form of the extracellular domain (55). By contrast, lapatinib treatment would impede
the efficacy of antibodies that bind to the open conformation of
the EGF receptor (50). The opposite would pertain to erlotinib,
which has already been shown to increase the binding of
mAb806, an antibody that is directed against an epitope available only in the untethered form of the EGF receptor (49). Thus,
attention to structural coupling in the EGF receptor could
enhance the synergy of extracellularly directed and intracellularly directed EGF receptor therapeutics.
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ligand. EC50 is the concentration of ligand needed to achieve
half-maximal binding and h is the Hill slope. Fitting was done
using GraphPad Prism 7.
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